Biotechnology News and Research

RSS

Maxwell Biotech, Sequella enter license agreement to commercialize SQ109 for TB treatment

Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, and Maxwell Biotech Venture Fund announced their agreement to complete the clinical development and commercialize SQ109 for treatment of tuberculosis in the Russian Federation and neighboring Commonwealth of Independent States countries, including Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine.

25 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011

Jeffrey Modell Foundation opens new center for primary immunodeficiency

The Jeffrey Modell Foundation today announced the opening of a new center at Johns Hopkins Children's Center dedicated to the early diagnosis and appropriate treatment of children with primary immunodeficiency, a group of potentially fatal conditions in which the immune system malfunctions or is missing.

22 Apr 2011

Coquitlam student earns top prize in 2011 British Columbia SABC competition

Ground-breaking research by a 17-year-old Coquitlam student who found a way to observe the effects of ethanol on early brain development in an intact and awake brain has earned him the top prize in the 2011 British Columbia sanofi-aventis BioTalent Challenge.

22 Apr 2011

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology, being held May 1-5, 2011 in Ft. Lauderdale, FL.

22 Apr 2011

FDA approves Spectrum's FUSILEV Injection to treat metastatic colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that the U.S. Food and Drug Administration has approved the Company's Supplemental New Drug Application for FUSILEV Injection.

22 Apr 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter International Inc. today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011.

From Baxter International Inc. 21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.

21 Apr 2011

ICON first quarter net revenue increases 4.6% to $229 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.

21 Apr 2011

KellBenx secures $2.5 million from initial funding round

KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.

21 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

ACT seeks European MHRA clearance to initiate hESC derived RPE cell Phase 1/2 study in SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has filed a clinical trial application (CTA) with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate its Phase 1/2 clinical trial using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD).

21 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Oncolytics announces interim data from REOLYSIN translational clinical trial in metastatic colorectal cancer

Oncolytics Biotech Inc. today announced interim data from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator of the study was Professor Alan Melcher of Leeds Institute of Molecular Medicine, University of Leeds, UK.

20 Apr 2011

bluebird bio announces receipt of additional $30 million in financing

bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that the company has secured an additional $30 million in financing.

20 Apr 2011